Deal aims to steal US sales of Lilly blockbuster drug
Privately-held generics firm Alvogen has paid to market Pfenex’s (NYSE: PFNX) copy of Forteo (teriparatide), an osteoporosis drug marketed by US pharma major Eli Lilly (NYSE: LLY), in the USA.
Pfenex’s PF708 is being developed through the 505(b)(2) regulatory pathway in the USA and based on positive trial results, the company plans to submit a New Drug Application (NDA) to the US Food and Drug Administration in the third quarter of 2018, leading to potential launch, if approved by regulators, as early as the third quarter of 2019.
"Alvogen's established commercial business with vast resources and experience will support us through the NDA submission, launch and commercialization"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze